Fractalkine mediates communication between pathogenic proteins and microglia: Implications of anti-inflammatory treatments in different stages of neurodegenerative diseases

International Journal of Alzheimer's Disease

Volumn , Issue , 2012, Pages

  Desforges, Nicole M ^a   Hebron, Michaeline L ^a   Algarzae, Norah K ^a   Lonskaya, Irina ^a   Moussa, Charbel E H ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIINFLAMMATORY AGENT; FRACTALKINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CELL ACTIVATION; CELL COMMUNICATION; CELL INTERACTION; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DISEASE COURSE; DOWN REGULATION; HUMAN; IMMUNOREGULATION; INFLAMMATION; INTRACELLULAR SIGNALING; MICROGLIA; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; REVIEW; TARGET CELL; UPREGULATION;

EID: 84866252499     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2012/345472     Document Type: Review

References (128)

1. Ransohoff R. M., Perry V. H., Microglial physiology: unique stimuli, specialized responses. Annual Review of Immunology 2009 27 119 145 2-s2.0-67650966680 10.1146/annurev.immunol.021908.132528
2. Streit W. J., Microglia as neuroprotective, immunocompetent cells of the CNS. GLIA 2002 40 2 133 139 2-s2.0-0036847816 10.1002/glia.10154
3. Takeuchi O., Akira S., Pattern recognition receptors and inflammation. Cell 2010 140 6 805 820 2-s2.0-77950343791 10.1016/j.cell.2010.01.022
4. Di Virgilio F., Ceruti S., Bramanti P., Abbracchio M. P., Purinergic signalling in inflammation of the central nervous system. Trends in Neurosciences 2009 32 2 79 87 2-s2.0-58949094359 10.1016/j.tins.2008.11.003
5. Brown G. C., Neher J. J., Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Molecular Neurobiology 2010 41 2-3 242 247 2-s2.0-77955085839 10.1007/s12035-010-8105-9
6. Balistreri C. R., Colonna-Romano G., Lio D., Candore G., Caruso C., TLR4 polymorphisms and ageing: implications for the pathophysiology of age-related diseases. Journal of Clinical Immunology 2009 29 4 406 415 2-s2.0-67651213832 10.1007/s10875-009-9297-5
7. Husemann J., Loike J. D., Anankov R., Febbraio M., Silverstein S. C., Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. GLIA 2002 40 2 195 205 2-s2.0-0036847848 10.1002/glia.10148
8. Nathan C., Ding A., Nonresolving inflammation. Cell 2010 140 6 871 882 2-s2.0-77950365906 10.1016/j.cell.2010.02.029
9. Khandelwal P. J., Herman A. M., Moussa C. E. H., Inflammation in the early stages of neurodegenerative pathology. Journal of Neuroimmunology 2011 238 1 1 11 2-s2.0-79961007105 10.1016/j.jneuroim.2011.07.002
10. Lumeng C. N., Bodzin J. L., Saltiel A. R., Obesity induces a phenotypic switch in adipose tissue macrophage polarization. Journal of Clinical Investigation 2007 117 1 175 184 2-s2.0-33846026712 10.1172/JCI29881
11. Nimmerjahn A., Kirchhoff F., Helmchen F., Neuroscience: resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005 308 5726 1314 1318 2-s2.0-19744380563 10.1126/science.1110647
12. Akiyama H., Barger S., Barnum S., Inflammation and Alzheimer's disease. Neurobiology of Aging 2000 21 3 383 421 2-s2.0-0034612175 10.1016/S0197-4580(00) 00124-X
13. Gebicke-Haerter P. J., Microglia in neurodegeneration: molecular aspects. Microscopy Research and Technique 2001 54 1 47 58 2-s2.0-0035399785 10.1002/jemt.1120
14. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R. B., Brooks D. J., In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease 2006 21 2 404 412 2-s2.0-30744472146 10.1016/j.nbd.2005.08.002
15. Ishizawa K., Dickson D. W., Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. Journal of Neuropathology and Experimental Neurology 2001 60 6 647 657 2-s2.0-0034996076
16. Dawson T. M., Dawson V. L., Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003 302 5646 819 822 2-s2.0-0242363670 10.1126/science.1087753
17. Di Maria E., Tabaton M., Vigo T., Abbruzzese G., Bellone E., Donati C., Frasson E., Marchese R., Montagna P., Munoz D. G., Pramstaller P. P., Zanusso G., Ajmar F., Mandich P., Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Annals of Neurology 2000 47 3 374 377 2-s2.0-0034011659 10.1002/1531-8249(200003)47:3374::AID-ANA15>3.0. CO;2-8
18. Dickson D. W., Tau and synuclein and their role in neuropathology. Brain Pathology 1999 9 4 657 661 2-s2.0-0032886707
19. Lippa S. M., Lippa C. F., Mori H., α -synuclein aggregation in pathological aging and Alzheimer's disease: the impact of β -amyloid plaque level. American Journal of Alzheimer's Disease and other Dementias 2005 20 5 315 318 2-s2.0-27144472378
20. Pletnikova O., West N., Lee M. K., Rudow G. L., Skolasky R. L., Dawson T. M., Marsh L., Troncoso J. C., A β deposition is associated with enhanced cortical α -synuclein lesions in Lewy body diseases. Neurobiology of Aging 2005 26 8 1183 1192 2-s2.0-19444363661 10.1016/j.neurobiolaging.2004.10.006
21. Popescu A., Lippa C. F., Lee V. M. Y., Trojanowski J. Q., Lewy bodies in the amygdala: increase of α -synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Archives of Neurology 2004 61 12 1915 1919 2-s2.0-10044281817 10.1001/archneur.61.12.1915
22. Yancopoulou D., Xuereb J. H., Crowther R. A., Hodges J. R., Spillantini M. G., Tau and α -synuclein inclusions in a case of familial frontotemporal dementia and progressive aphasia. Journal of Neuropathology and Experimental Neurology 2005 64 3 245 253 2-s2.0-15244354724
23. Buée L., Bussière T., Buée-Scherrer V., Delacourte A., Hof P. R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Research Reviews 2000 33 1 95 130 2-s2.0-0033850407 10.1016/S0165-0173(00)00019-9
24. Kitazawa M., Yamasaki T. R., LaFerla F. M., Microglia as a potential bridge between the amyloid β -peptide and tau. Annals of the New York Academy of Sciences 2004 1035 85 103 2-s2.0-14944367845 10.1196/annals.1332.006
25. Yoshiyama Y., Higuchi M., Zhang B., Huang S. M., Iwata N., Saido T., Maeda J., Suhara T., Trojanowski J. Q., Lee V. M. Y., Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007 53 3 337 351 2-s2.0-33846538660 10.1016/j.neuron.2007.01.010
26. Khandelwal P. J., Dumanis S. B., Herman A. M., Rebeck G. W., Moussa C. E.-H., Wild type and P301L mutant Tau promote neuro-inflammation and α -Synuclein accumulation in lentiviral gene delivery models. Molecular and Cellular Neuroscience 2012 49 1 44 53 2-s2.0-84155162961 10.1016/j.mcn.2011.09. 002
27. Li Y., Liu L., Barger S. W., Griffin W. S. T., Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. Journal of Neuroscience 2003 23 5 1605 1611 2-s2.0-0037336701
28. Quintanilla R. A., Orellana D. I., González-Billault C., Maccioni R. B., Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Experimental Cell Research 2004 295 1 245 257 2-s2.0-1642420308 10.1016/j.yexcr.2004.01.002
29. Saez E. T., Pehar M., Vargas M., Barbeito L., Maccioni R. B., Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. In Vivo 2004 18 3 275 280 2-s2.0-4043058045
30. Frank-Cannon T. C., Alto L. T., McAlpine F. E., Tansey M. G., Does neuroinflammation fan the flame in neurodegenerative diseases? Molecular Neurodegeneration 2009 4 1, article 47 2-s2.0-72449204160 10.1186/1750-1326-4-47
31. Wyss-Coray T., Mucke L., Inflammation in neurodegenerative diseasea double-edged sword. Neuron 2002 35 3 419 432 2-s2.0-0036685522 10.1016/S0896-6273(02)00794-8
32. Cameron B., Landreth G. E., Inflammation, microglia, and alzheimer's disease. Neurobiology of Disease 2010 37 3 503 509 2-s2.0-75949127362 10.1016/j.nbd.2009.10.006
33. Bazan J. F., Bacon K. B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D. R., Zlotnik A., Schall T. J., A new class of membrane-bound chemokine with a CX3C motif. Nature 1997 385 6617 640 642 2-s2.0-0031036347 10.1038/385640a0
34. Harrison J. K., Jiang Y., Chen S., Xia Y., Maciejewski D., Mcnamara R. K., Streit W. J., Salafranca M. N., Adhikari S., Thompson D. A., Botti P., Bacon K. B., Feng L., Role for neuronally derived fractalkine in mediating interactions between neurons and Cx3cr1 -expressing microglia. Proceedings of the National Academy of Sciences of the United States of America 1998 95 18 10896 10901 2-s2.0-13144279282 10.1073/pnas.95.18.10896
35. Hatori K., Nagai A., Heisel R., Ryu J. K., Kim S. U., Fractalkine and fractalkine receptors in human neurons and glial cells. Journal of Neuroscience Research 2002 69 3 418 426 2-s2.0-0036682239 10.1002/jnr.10304
36. Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., Kakizaki M., Takagi S., Nomiyama H., Schall T. J., Yoshie O., Identification and molecular characterization of fractalkine receptor Cx3cr1, which mediates both leukocyte migration and adhesion. Cell 1997 91 4 521 530 2-s2.0-0030723388
37. Pan Y., Lloyd C., Zhou H., Dolich S., Deeds J., Gonzalo J. A., Vath J., Gosselin M., Ma J., Dussault B., Woolf E., Alperin G., Culpepper J., Gutierrez-Ramos J. C., Gearing D., Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997 387 6633 611 617 2-s2.0-0030949298 10.1038/42491
38. Yoneda O., Imai T., Goda S., Inoue H., Yamauchi A., Okazaki T., Imai H., Yoshie O., Bloom E. T., Domae N., Umehara H., Fractalkine-mediated endothelial cell injury by NK cells. Journal of Immunology 2000 164 8 4055 4062 2-s2.0-17544396739
39. Tong N., Perry S. W., Zhang Q., James H. J., Guo H., Brooks A., Bal H., Kinnear S. A., Fine S., Epstein L. G., Dairaghi D., Schall T. J., Gendelman H. E., Dewhurst S., Sharer L. R., Gelbard H. A., Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. Journal of Immunology 2000 164 3 1333 1339 2-s2.0-0034141496
40. Bhaskar K., Konerth M., Kokiko-Cochran O. N., Cardona A., Ransohoff R. M., Lamb B. T., Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010 68 1 19 31 2-s2.0-77957321869 10.1016/j.neuron.2010.08.023
41. Cardona A. E., Sasse M. E., Liu L., Cardona S. M., Mizutani M., Savarin C., Hu T., Ransohoff R. M., Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand In circulation and tissues. Blood 2008 112 2 256 263 2-s2.0-47649113481 10.1182/blood-2007-10- 118497
42. Liu Z., Condello C., Schain A., Harb R., Grutzendler J., Cx3cr1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid- β phagocytosis. Journal of Neuroscience 2010 30 50 17091 17101 2-s2.0-78650338241 10.1523/JNEUROSCI.4403-10.2010
43. Cho S.-H., Sun B., Zhou Y., Kauppinen T. M., Halabisky B., Wes P., Ransohoff R. M., Gan L., Cx3cr1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. Journal of Biological Chemistry 2011 286 37 32713 32722 2-s2.0-80052714655 10.1074/jbc.M111.254268
44. 1) in inflammatory diseases of the nervous system. Journal of Neuroimmunology 2003 137 1-2 210 217 2-s2.0-0037379079 10.1016/S0165-5728(03)00085-7
45. Rancan M., Bye N., Otto V. I., Trentz O., Kossmann T., Frentzel S., Morganti-Kossmann M. C., The chemokine Fractalkine in patients with severe traumatic brain injury and a mouse model of closed head injury. Journal of Cerebral Blood Flow and Metabolism 2004 24 10 1110 1118 2-s2.0-4944228603 10.1097/01.WCB.0000133470.91843.72
46. Sporer B., Kastenbauer S., Koedel U., Arendt G., Pfister H. W., Increased intrathecal release of soluble fractalkine in HIV-infected patients. AIDS Research and Human Retroviruses 2003 19 2 111 116 2-s2.0-0037295646 10.1089/088922203762688612
47. Combadière C., Feumi C., Raoul W., Keller N., Rodéro M., Pézard A., Lavalette S., Houssier M., Jonet L., Picard E., Debré P., Sirinyan M., Deterre P., Ferroukhi T., Cohen S. Y., Chauvaud D., Jeanny J. C., Chemtob S., Behar-Cohen F., Sennlaub F., Cx3cr1 -dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. Journal of Clinical Investigation 2007 117 10 2920 2928 2-s2.0-34948898131 10.1172/JCI31692
48. Duan R. S., Yang X., Chen Z. G., Lu M. O., Morris C., Winblad B., Zhu J., Decreased fractalkine and increased IP-10 expression in aged brain of APPswe transgenic mice. Neurochemical Research 2008 33 6 1085 1089 2-s2.0-41949141716 10.1007/s11064-007-9554-z
49. Lim J.-E., Kou J., Song M., Pattanayak A., Jin J., Lalonde R., Fukuchi K.-I., MyD88 deficiency ameliorates β -amyloidosis in an animal model of Alzheimer's disease. American Journal of Pathology 2011 179 3 1095 1103 2-s2.0-80052836312 10.1016/j.ajpath.2011.05.045
50. Lee S., Varvel N. H., Konerth M. E., Xu G., Cardona A. E., Ransohoff R. M., Lamb B. T., Cx3cr1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. American Journal of Pathology 2010 177 5 2549 2562 2-s2.0-77957316313 10.2353/ajpath.2010.100265
51. Fuhrmann M., Bittner T., Jung C. K. E., Burgold S., Page R. M., Mitteregger G., Haass C., Laferla F. M., Kretzschmar H., Herms J., Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nature Neuroscience 2010 13 4 411 413 2-s2.0-77950188666 10.1038/nn.2511
52. Tromba C., Cohen I. S., A novel action of isoproterenol to inactivate a cardiac K+ current is not blocked by beta and alpha adrenergic blockers. Biophysical Journal 1990 58 3 791 795 2-s2.0-0025160999
53. Zujovic V., Benavides J., Vigé X., Carter C., Taupin V., Fractalkine modulates TNF- α secretion and neurotoxicity induced by microglial activation. GLIA 2000 29 4 305 315 2-s2.0-0034652697 10.1002/(SICI)1098-1136(20000215)29:4305::AID-GLIA2>3.0.CO;2-V
54. 1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. Journal of Neuroimmunology 2005 166 1-2 19 28 2-s2.0-23044464868 10.1016/j.jneuroim.2005.03.023
55. Meucci O., Fatatis A., Simen A. A., Bushell T. J., Gray P. W., Miller R. J., Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America 1998 95 24 14500 14505 2-s2.0-0032564406 10.1073/pnas.95.24.14500
56. Mizuno T., Kawanokuchi J., Numata K., Suzumura A., Production and neuroprotective functions of fractalkine in the central nervous system. Brain Research 2003 979 1-2 65 70 2-s2.0-0037821637 10.1016/S0006-8993(03)02867-1
57. Cardona A. E., Pioro E. P., Sasse M. E., Kostenko V., Cardona S. M., Dijkstra I. M., Huang D., Kidd G., Dombrowski S., Dutta R., Lee J. C., Cook D. N., Jung S., Lira S. A., Littman D. R., Ransohoff R. M., Control of microglial neurotoxicity by the fractalkine receptor. Nature Neuroscience 2006 9 7 917 924 2-s2.0-33745573660 10.1038/nn1715
58. Denes A., Ferenczi S., Halász J., Környei Z., Kovács K. J., Role of Cx3cr1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. Journal of Cerebral Blood Flow and Metabolism 2008 28 10 1707 1721 2-s2.0-52549109505 10.1038/jcbfm.2008.64
59. Hardy J., Selkoe D. J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002 297 5580 353 356 2-s2.0-0037135111 10.1126/science.1072994
60. Selkoe D. J., Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nature Cell Biology 2004 6 11 1054 1061 2-s2.0-7944233158 10.1038/ncb1104-1054
61. Hardy J., Alzheimer's disease: genetic evidence points to a single pathogenesis. Annals of Neurology 2003 54 2 143 144 2-s2.0-0042845877 10.1002/ana.10624
62. Jarrett J. T., Berger E. P., Lansbury P. T., The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993 32 18 4693 4697 2-s2.0-0027258525
63. Allinson T. M. J., Parkin E. T., Turner A. J., Hooper N. M., ADAMs family members as amyloid precursor protein α -secretases. Journal of Neuroscience Research 2003 74 3 342 352 2-s2.0-0242330374 10.1002/jnr.10737
64. Li Q. X., Maynard C., Cappai R., McLean C. A., Cherny R. A., Lynch T., Culvenor J. G., Trevaskis J., Tanner J. E., Bailey K. A., Czech C., Bush A. I., Beyreuther K., Masters C. L., Intracellular accumulation of detergent-soluble amyloidogenic A β fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice. Journal of Neurochemistry 1999 72 6 2479 2487 2-s2.0-0033051445 10.1046/j.1471-4159.1999.0722479.x
65. Bertram L., Tanzi R. E., Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nature Reviews Neuroscience 2008 9 10 768 778 2-s2.0-52449089987 10.1038/nrn2494
66. Von Kienlin M., Künnecke B., Metzger F., Steiner G., Richards J. G., Ozmen L., Jacobsen H., Loetscher H., Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiology of Disease 2005 18 1 32 39 2-s2.0-11844258289 10.1016/j.nbd.2004. 09.005
67. Oddo S., Caccamo A., Smith I. F., Green K. N., LaFerla F. M., A dynamic relationship between intracellular and extracellular pools of A β American Journal of Pathology 2006 168 1 184 194 2-s2.0-30344448543 10.2353/ajpath.2006. 050593
68. Gyure K. A., Durham R., Stewart W. F., Smialek J. E., Troncoso J. C., Intraneuronal A β -amyloid precedes development of amyloid plaques in Down syndrome. Archives of Pathology and Laboratory Medicine 2001 125 4 489 492 2-s2.0-0034745017
69. Mori C., Spooner E. T., Wisniewski K. E., Wisniewski T. M., Yamaguchi H., Saido T. C., Tolan D. R., Selkoe D. J., Lemere C. A., Intraneuronal A β 42 accumulation in Down syndrome brain. Amyloid 2002 9 2 88 102 2-s2.0-0035997524
70. Ohyagi Y., Tsuruta Y., Motomura K., Miyoshi K., Kikuchi H., Iwaki T., Taniwaki T., Kira J. I., Intraneuronal amyloid β 42 enhanced by heating but counteracted by formic acid. Journal of Neuroscience Methods 2007 159 1 134 138 2-s2.0-33751248758 10.1016/j.jneumeth.2006.06.010
71. 1-42 clearance. Human Molecular Genetics 2009 18 17 3206 3216 2-s2.0-68749107083 10.1093/hmg/ddp258
72. 1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. Journal of Biological Chemistry 2010 285 10 7440 7446 2-s2.0-77951226607 10.1074/jbc.M109.083915
73. Pereira C., Agostinho P., Moreira P. I., Cardoso S. M., Oliveira C. R., Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. Current Drug Targets 2005 4 4 383 403 2-s2.0-23144463734 10.2174/1568007054546117
74. Brown A. M., Finch S. J., Gordon D., Genome-wide association study of genetic loci and Alzheimer disease. Journal of the American Medical Association 2010 304 8 858 2-s2.0-77955936578 10.1001/jama.2010.1172
75. Hollingworth P., Harold D., Sims R., Gerrish A., Lambert J. C., Carrasquillo M. M., Abraham R., Hamshere M. L., Pahwa J. S., Moskvina V., Dowzell K., Jones N., Stretton A., Thomas C., Richards A., Ivanov D., Widdowson C., Chapman J., Lovestone S., Powell J., Proitsi P., Lupton M. K., Brayne C., Rubinsztein D. C., Gill M., Lawlor B., Lynch A., Brown K. S., Passmore P. A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A. D., Beaumont H., Warden D., Wilcock G., Love S., Kehoe P. G., Hooper N. M., Vardy E. R. L. C., Hardy J., Mead S., Fox N. C., Rossor M., Collinge J., Maier W., Jessen F., Rüther E., Schürmann B., Heun R., Kölsch H., Van Den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frölich L., Hampel H., Gallacher J., Hüll M., Rujescu D., Giegling I., Goate A. M., Kauwe J. S. K., Cruchaga C., Nowotny P., Morris J. C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P. P., Van Broeckhoven C., Livingston G., Bass N. J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C. E., Tsolaki M., Singleton A. B., Guerreiro R., Mühleisen T. W., Nöthen M. M., Moebus S., Jöckel K. H., Klopp N., Wichmann H. E., Pankratz V. S., Sando S. B., Aasly J. O., Barcikowska M., Wszolek Z. K., Dickson D. W., Graff-Radford N. R., Petersen R. C., Van Duijn C. M., Breteler M. M. B., Ikram M. A., Destefano A. L., Fitzpatrick A. L., Lopez O., Launer L. J., Seshadri S., Berr C., Campion D., Epelbaum J., Dartigues J. F., Tzourio C., Alpérovitch A., Lathrop M., Feulner T. M., Friedrich P., Riehle C., Krawczak M., Schreiber S., Mayhaus M., Nicolhaus S., Wagenpfeil S., Steinberg S., Stefansson H., Stefansson K., SnÆdal J., Björnsson S., Jonsson P. V., Chouraki V., Genier-Boley B., Hiltunen M., Soininen H., Combarros O., Zelenika D., Delepine M., Bullido M. J., Pasquier F., Mateo I., Frank-Garcia A., Porcellini E., Hanon O., Coto E., Alvarez V., Bosco P., Siciliano G., Mancuso M., Panza F., Solfrizzi V., Nacmias B., Sorbi S., Bossù P., Piccardi P., Arosio B., Annoni G., Seripa D., Pilotto A., Scarpini E., Galimberti D., Brice A., Hannequin D., Licastro F., Jones L., Holmans P. A., Jonsson T., Riemenschneider M., Morgan K., Younkin S. G., Owen M. J., O'Donovan M., Amouyel P., Williams J., Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics 2011 43 5 429 436 2-s2.0-79955484414 10.1038/ng.803
76. Rogers J., Webster S., Lue L.-F., Brachova L., Civin W. H., Emmerling M., Shivers B., Walker D., McGeer P., Inflammation and Alzheimer's disease pathogenesis. Neurobiology of Aging 1996 17 5 681 686 2-s2.0-0030250567 10.1016/0197-4580(96)00115-7
77. Savarin-Vuaillat C., Ransohoff R. M., Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics 2007 4 4 590 601 2-s2.0-34848825439 10.1016/j.nurt.2007.07.004
78. Hoarau J. J., Krejbich-Trotot P., Jaffar-Bandjee M. C., Das T., Thon-Hon G. V., Kumar S., Neal J. W., Gasque P., Activation and control of CNS innate immune responses in health and diseases: a balancing act finely tuned by neuroimmune regulators (NIReg). CNS & Neurological Disorders Drug Targets 2011 10 1 25 43 2-s2.0-79961011276
79. Rezai-Zadeh K., Gate D., Gowing G., Town T., How to get from here to there: macrophage recruitment in Alzheimer's disease. Current Alzheimer Research 2011 8 2 156 163 2-s2.0-79954514213
80. Mizuno T., The biphasic role of microglia in Alzheimer's disease. International Journal of Alzheimer's Disease 2012 2012 737846 2-s2.0-84862297464 10.1155/2012/737846
81. Kim T. S., Lim H. K., Lee J. Y., Kim D. J., Park S., Lee C., Lee C. U., Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neuroscience Letters 2008 436 2 196 200 2-s2.0-41949125406 10.1016/j.neulet.2008.03.019
82. Younkin S. G., The role of A β 42 in Alzheimer's disease. Journal of Physiology Paris 1998 92 3-4 289 292 2-s2.0-0032105394 10.1016/S0928-4257(98) 80035-1
83. Goedert M., Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and α -synucleinopathies. Philosophical Transactions of the Royal Society B 1999 354 1386 1101 1118 2-s2.0-0033614777
84. Goedert M., Alpha-synuclein and neurodegenerative diseases. Nature Reviews Neuroscience 2001 2 7 492 501 2-s2.0-0035409575 10.1038/35081564
85. Lundvig D., Lindersson E., Jensen P. H., Pathogenic effects of α -synuclein aggregation. Molecular Brain Research 2005 134 1 3 17 2-s2.0-15544371311 10.1016/j.molbrainres.2004.09.001
86. Grazia Spillantini M., Anthony Crowther R., Jakes R., Cairns N. J., Lantos P. L., Goedert M., Filamentous α -synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience Letters 1998 251 3 205 208 2-s2.0-0032584686
87. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M., Goedert M., α -Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proceedings of the National Academy of Sciences of the United States of America 1998 95 11 6469 6473 2-s2.0-0032568534 10.1073/pnas.95.11.6469
88. Spillantini M. G., Goedert M., The α -synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Annals of the New York Academy of Sciences 2000 920 16 27 2-s2.0-0034531475
89. Spillantini M. G., Schmidt M. L., Lee V. M. Y., Trojanowski J. Q., Jakes R., Goedert M., α -synuclein in Lewy bodies. Nature 1997 388 6645 839 840 2-s2.0-0030882856 10.1038/42166
90. Takeda A., Hashimoto M., Mallory M., Sundsumo M., Hansen L., Masliah E., C-terminal α -synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathologica 2000 99 3 296 304 2-s2.0-0033954218
91. Trojanowski J. Q., Lee V. M. Y., Parkinson's disease and related α -synucleinopathies are brain amyloidoses. Annals of the New York Academy of Sciences 2003 991 107 110 2-s2.0-0038727850
92. Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M., Takahashi H., NACP, a presynaptic protein, immunoreactivity in lewy bodies in Parkinson's disease. Neuroscience Letters 1997 239 1 45 48 2-s2.0-0031566042 10.1016/S0304-3940(97)00891-4
93. Gasser T., Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Reviews in Molecular Medicine 2009 11 e22 2-s2.0-69149089036 10.1017/S1462399409001148
94. Cookson M. R., Bandmann O., Parkinson's disease: insights from pathways. Human Molecular Genetics 2010 19 1 R21 R27 2-s2.0-77953890085 10.1093/hmg/ddq167 ddq167
95. Healy D. G., Abou-Sleiman P. M., Lees A. J., Casas J. P., Quinn N., Bhatia K., Hingorani A. D., Wood N. W., Tau gene and Parkinson's disease: a case-control study and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry 2004 75 7 962 965 2-s2.0-3042797560 10.1136/jnnp.2003.026203
96. Martin-Villalba A., Hahne M., Kleber S., Vogel J., Falk W., Schenkel J., Krammer P. H., Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death and Differentiation 2001 8 7 679 686 2-s2.0-0034915133 10.1038/sj.cdd.4400882
97. Benner E. J., Banerjee R., Reynolds A. D., Sherman S., Pisarev V. M., Tsiperson V., Nemachek C., Ciborowski P., Przedborski S., Mosley R. L., Gendelman H. E., Nitrated α -synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS ONE 2008 3 1 2-s2.0-38949151035 10.1371/journal.pone.0001376 e1376
98. Kuhn D. M., Francescutti-Verbeem D. M., Thomas D. M., Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Annals of the New York Academy of Sciences 2006 1074 31 41 2-s2.0-33749569201 10.1196/annals.1369.003
99. Reynolds A. D., Kadiu I., Garg S. K., Glanzer J. G., Nordgren T., Ciborowski P., Banerjee R., Gendelman H. E., Nitrated alpha-synuclein and microglial neuroregulatory activities. Journal of NeuroImmune Pharmacology 2008 3 2 59 74 2-s2.0-43449090378 10.1007/s11481-008-9100-z
100. Chin S. S. M., Goldman J. E., Glial inclusions in CNS degenerative diseases. Journal of Neuropathology and Experimental Neurology 1996 55 5 499 508 2-s2.0-0029879877
101. Tu P. H., Elder G., Lazzarini R. A., Nelson D., Trojanowski J. Q., Lee V. M. Y., Overexpression of the human NFM subunit in transgenic mice modifies the level of endogenous NFL and the phosphorylation state of NFH subunits. Journal of Cell Biology 1995 129 6 1629 1640 2-s2.0-0029052277 10.1083/jcb.129.6.1629
102. Roodveldt C., Christodoulou J., Dobson C. M., Immunological features of α -synuclein in Parkinson's disease. Journal of Cellular and Molecular Medicine 2008 12 5B 1820 1829 2-s2.0-55249087467 10.1111/j.1582-4934.2008.00450. x
103. Zhang W., Wang T., Pei Z., Miller D. S., Wu X., Block M. L., Wilson B., Zhang W., Zhou Y., Hong J. S., Zhang J., Aggregated α -synuclein activates microglia: a process leading to disease progression in Parkinson's disease. The FASEB Journal 2005 19 6 533 542 2-s2.0-20144389524 10.1096/fj.04-2751com
104. Hirsch E. C., Hunot S., Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology 2009 8 4 382 397 2-s2.0-62549133546 10.1016/S1474-4422(09)70062-6
105. Castaño A., Herrera A. J., Cano J., Machado A., Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. Journal of Neurochemistry 1998 70 4 1584 1592 2-s2.0-0031881687
106. Hunter R. L., Dragicevic N., Seifert K., Choi D. Y., Liu M., Kim H. C., Cass W. A., Sullivan P. G., Bing G., Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. Journal of Neurochemistry 2007 100 5 1375 1386 2-s2.0-33847005101 10.1111/j.1471-4159.2006.04327.x
107. 1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. Journal of Neuroinflammation 2011 8, article 9 2-s2.0-78951475702 10.1186/1742-2094-8-9
108. 1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease. Neurobiology of Aging 2011 32 3 443 458 2-s2.0-79952902015 10.1016/j.neurobiolaging.2009.03.004
109. Shi M., Bradner J., Hancock A. M., Chung K. A., Quinn J. F., Peskind E. R., Galasko D., Jankovic J., Zabetian C. P., Kim H. M., Leverenz J. B., Montine T. J., Ginghina C., Kang U. J., Cain K. C., Wang Y., Aasly J., Goldstein D., Zhang J., Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology 2011 69 3 570 580 2-s2.0-79953283868 10.1002/ana.22311
110. Martin B. K., Szekely C., Brandt J., Piantadosi S., Breitner J. C. S., Craft S., Evans D., Green R., Mullan M., Cognitive function over time in the Alzheimer's disease anti-inflammatory prevention trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Archives of Neurology 2008 65 7 896 905 2-s2.0-47549107705 10.1001/archneur.2008.65.7.nct70006
111. Gao H. M., Liu B., Zhang W., Hong J. S., Novel anti-inflammatory therapy for Parkinson's disease. Trends in Pharmacological Sciences 2003 24 8 395 401 2-s2.0-0043162103 10.1016/S0165-6147(03)00176-7
112. Allan S. M., Rothwell N. J., Cytokines and acute neurodegeneration. Nature Reviews Neuroscience 2001 2 10 734 744 2-s2.0-0035487313 10.1038/35094583
113. Allan S. M., Tyrrell P. J., Rothwell N. J., Interleukin-1 and neuronal injury. Nature Reviews Immunology 2005 5 8 629 640 2-s2.0-23444441962 10.1038/nri1664
114. Liu Y., Walter S., Stagi M., Cherny D., Letiembre M., Schulz-Schaeffer W., Heine H., Penke B., Neumann H., Fassbender K., LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 2005 128 8 1778 1789 2-s2.0-23444448277 10.1093/brain/awh531
115. Combarros O., Infante J., Rodríguez E., Llorca J., Peña N., Fernández-Viadero C., Berciano J., CD14 receptor polymorphism and Alzheimer's disease risk. Neuroscience Letters 2005 380 1-2 193 196 2-s2.0-18044380916 10.1016/j.neulet.2005.01.082
116. Chen K., Iribarren P., Hu J., Chen J., Gong W., Cho E. H., Lockett S., Dunlop N. M., Ji M. W., Activation of toll-like receptor 2 on microglia promotes cell uptake of alzheimer disease-associated amyloid β peptide. Journal of Biological Chemistry 2006 281 6 3651 3659 2-s2.0-33645650780 10.1074/jbc.M508125200
117. Fiala M., Liu P. T., Espinosa-Jeffrey A., Rosenthal M. J., Bernard G., Ringman J. M., Sayre J., Zhang L., Zaghi J., Dejbakhsh S., Chiang B., Hui J., Mahanian M., Baghaee A., Hong P., Cashman J., Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proceedings of the National Academy of Sciences of the United States of America 2007 104 31 12849 12854 2-s2.0-34547889114 10.1073/pnas.0701267104
118. 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. Journal of Neuroscience 2008 28 22 5784 5793 2-s2.0-45949106077 10.1523/JNEUROSCI.1146-08.2008
119. Majumdar A., Cruz D., Asamoah N., Buxbaum A., Sohar I., Lobel P., Maxfield F. R., Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Molecular Biology of the Cell 2007 18 4 1490 1496 2-s2.0-34247264399 10.1091/mbc.E06-10-0975
120. Boissonneault V., Filali M., Lessard M., Relton J., Wong G., Rivest S., Powerful beneficial effects of macrophage colony-stimulating factor on β -amyloid deposition and cognitive impairment in Alzheimers disease. Brain 2009 132 4 1078 1092 2-s2.0-65249119363 10.1093/brain/awn331
121. Glezer I., Bittencourt J. C., Rivest S., Neuronal expression of Cd36, Cd44, and Cd83 antigen transcripts maps to distinct and specific murine brain circuits. Journal of Comparative Neurology 2009 517 6 906 924 2-s2.0-70449494862 10.1002/cne.22185
122. Garden G. A., Möller T., Microglia biology in health and disease. Journal of Neuroimmune Pharmacology 2006 1 2 127 137 2-s2.0-33747463996 10.1007/s11481-006-9015-5
123. Stolzing A., Grune T., Neuronal apoptotic bodies: phagocytosis and degradation by primary microglial cells. The FASEB Journal 2004 18 6 743 745 2-s2.0-3042738397
124. Witting A., Müller P., Herrmann A., Kettenmann H., Nolte C., Phagocytic clearance of apoptotic neurons by microglia/brain macrophages in vitro: Involvement of lectin-, integrin-, and phosphatidylserine-mediated recognition. Journal of Neurochemistry 2000 75 3 1060 1070 2-s2.0-0033836217 10.1046/j.1471-4159.2000.0751060.x
125. Silva M. T., do Vale A., dos Santos N. M. N., Secondary necrosis in multicellular animals: an outcome of apoptosis with pathogenic implications. Apoptosis 2008 13 4 463 482 2-s2.0-41149115987 10.1007/s10495-008-0187-8
126. Lauber K., Blumenthal S. G., Waibel M., Wesselborg S., Clearance of apoptotic cells: getting rid of the corpses. Molecular Cell 2004 14 3 277 287 2-s2.0-2342584674 10.1016/S1097-2765(04)00237-0
127. Ren Y., Savill J., Apoptosis: the importance of being eaten. Cell Death and Differentiation 1998 5 7 563 568 2-s2.0-0031819579
128. Glass C. K., Saijo K., Winner B., Marchetto M. C., Gage F. H., Mechanisms underlying inflammation in neurodegeneration. Cell 2010 140 6 918 934 2-s2.0-77950363010 10.1016/j.cell.2010.02.016